BERANDA RESMI
Login Internal
ARC Institute
WATCHDOG · CENTRE OF EXCELLENCE

Mengawal mutu obat dan pedoman klinis Indonesia

Watchdog independen yang memetakan dua hal: obat mana yang seharusnya dikaji lewat Fornas tapi belum (pilar Obat), dan topik klinis mana yang seharusnya punya PNPK tapi belum (pilar Pedoman). Sumber bukti: NICE UK + WHO.

Pilar Obat

Obat & HTA

Obat mana yang Indonesia belum jamin?

1.366
Obat unik
65
Prioritas 1
715
Prioritas 2

NICE Drug HTA + WHO Essential Medicines List dibandingkan dengan Fornas (Kemenkes) + INAPROC (e-katalog LKPP).

NICE HTA + WHO EMLvs Fornas + INAPROCDaftar HTA priority
Buka pilar Obat Browse 924 NICE appraisal
NICE × WHO EML × Fornas
Persebaran obat lintas-sumber NICE, WHO EML, dan FornasDiagram Venn tiga lingkaran. Total 1.283 obat unik dengan kode ATC di setidaknya satu sumber. NICE only: 309. EML only: 406. Fornas only: 151. NICE dan EML: 65. NICE dan Fornas: 17. EML dan Fornas: 293. Ketiganya: 42.NICEWHO EMLFORNAS309NICE only406EML only151Fornas only65NICE+EML17NICE+Fornas293EML+Fornas42all three
Pilar Pedoman Klinis

PNPK & Pedoman

Topik klinis mana yang Indonesia belum punya PNPK?

57
PNPK topik
128
Prioritas 1
62
Prioritas 2

NICE clinical guideline + WHO UHC Compendium dibandingkan dengan PNPK Kemenkes RI + SPK Nasional.

NICE NG/CG + UHC Compendiumvs PNPK KemenkesKandidat penyusunan PNPK
Buka pilar Pedoman Browse struktur asli
NICE × UHC × PNPK
Persebaran topik klinis lintas-korpus UHC, NICE, dan IndonesiaDiagram Venn tiga lingkaran pada level topik klinis. Total 183 topik unik. UHC only: 42. NICE only: 32. Indonesia only: 4. UHC dan NICE: 55. UHC dan Indonesia: 12. NICE dan Indonesia: 2. Ketiganya: 36.UHCNICEIndonesia42UHC only32NICE only4Indonesia only55UHC + NICE12UHC + ID2NICE + ID36all three
🆕 New HTA · ARC QALY Engine v0.1

Drug dengan ΔQALY + ICER ter-hitung untuk Indonesia

AI-baseline parametric Markov + PSA 10K iterasi. Threshold WHO-CHOICE 1×/3× PDB. Draft — butuh validasi health economist.

66 Prioritas 1 · v0.1
L01FF02ΔQALY
pembrolizumab
Antineoplastic and immunomodulating agents
ΔQALY mean
0.887
ICER (Rp/QALY)
11.8 M
✗ above threshold · 0% prob CE @ 1× PDB
L01FF01ΔQALY
nivolumab
Antineoplastic and immunomodulating agents
ΔQALY mean
0.887
ICER (Rp/QALY)
11.8 M
✗ above threshold · 0% prob CE @ 1× PDB
L01FF05ΔQALY
atezolizumab
Antineoplastic and immunomodulating agents
ΔQALY mean
0.887
ICER (Rp/QALY)
11.4 M
✗ above threshold · 0% prob CE @ 1× PDB
L01FG01ΔQALY
bevacizumab
Antineoplastic and immunomodulating agents
ΔQALY mean
0.333
ICER (Rp/QALY)
8.8 M
✗ above threshold · 0% prob CE @ 1× PDB
L01EL01ΔQALY
ibrutinib
Antineoplastic and immunomodulating agents
ΔQALY mean
1.585
ICER (Rp/QALY)
3.1 M
✗ above threshold · 0% prob CE @ 1× PDB
L01FC01ΔQALY
daratumumab
Antineoplastic and immunomodulating agents
ΔQALY mean
3.525
ICER (Rp/QALY)
281.6 jt
✗ above threshold · 1% prob CE @ 1× PDB
L01FF03ΔQALY
durvalumab
Antineoplastic and immunomodulating agents
ΔQALY mean
1.107
ICER (Rp/QALY)
6.7 M
✗ above threshold · 0% prob CE @ 1× PDB
L04AB04ΔQALY
adalimumab
Antineoplastic and immunomodulating agents
ΔQALY mean
0.747
ICER (Rp/QALY)
2.0 M
✗ above threshold · 0% prob CE @ 1× PDB
A10BK01ΔQALY
dapagliflozin
Alimentary tract and metabolism
ΔQALY mean
1.322
ICER (Rp/QALY)
-18189 rb
DOMINANT · 100% prob CE @ 1× PDB
A10BK03ΔQALY
empagliflozin
Alimentary tract and metabolism
ΔQALY mean
0.785
ICER (Rp/QALY)
-19737 rb
DOMINANT · 100% prob CE @ 1× PDB
L01EL03ΔQALY
zanubrutinib
Antineoplastic and immunomodulating agents
ΔQALY mean
2.288
ICER (Rp/QALY)
-1288 rb
DOMINANT · 73% prob CE @ 1× PDB
L02BB04ΔQALY
enzalutamide
Antineoplastic and immunomodulating agents
ΔQALY mean
0.878
ICER (Rp/QALY)
2.9 M
✗ above threshold · 0% prob CE @ 1× PDB
L01EB04ΔQALY
osimertinib
Antineoplastic and immunomodulating agents
ΔQALY mean
2.885
ICER (Rp/QALY)
157.7 jt
✓ acceptable 3× PDB · 5% prob CE @ 1× PDB
L01EC02ΔQALY
dabrafenib
Antineoplastic and immunomodulating agents
ΔQALY mean
1.730
ICER (Rp/QALY)
2.3 M
✗ above threshold · 0% prob CE @ 1× PDB
L01FF06ΔQALY
cemiplimab
Antineoplastic and immunomodulating agents
ΔQALY mean
1.107
ICER (Rp/QALY)
5.8 M
✗ above threshold · 0% prob CE @ 1× PDB
L01FX07ΔQALY
blinatumomab
Antineoplastic and immunomodulating agents
ΔQALY mean
0.710
ICER (Rp/QALY)
6.9 M
✗ above threshold · 0% prob CE @ 1× PDB
L03AB10ΔQALY
peginterferon alfa-2b
Antineoplastic and immunomodulating agents
ΔQALY mean
1.573
ICER (Rp/QALY)
-4665 rb
DOMINANT · 100% prob CE @ 1× PDB
L04AB02ΔQALY
infliximab
Antineoplastic and immunomodulating agents
ΔQALY mean
0.747
ICER (Rp/QALY)
2.7 M
✗ above threshold · 0% prob CE @ 1× PDB
L04AC05ΔQALY
ustekinumab
Antineoplastic and immunomodulating agents
ΔQALY mean
0.747
ICER (Rp/QALY)
3.2 M
✗ above threshold · 0% prob CE @ 1× PDB
A10BK02ΔQALY
canagliflozin
Alimentary tract and metabolism
ΔQALY mean
0.851
ICER (Rp/QALY)
204.2 jt
✓ acceptable 3× PDB · 0% prob CE @ 1× PDB
B01AF02ΔQALY
apixaban
Blood and blood forming organs
ΔQALY mean
0.986
ICER (Rp/QALY)
4.3 jt
✓ cost-effective · 100% prob CE @ 1× PDB
L01EA02ΔQALY
dasatinib
Antineoplastic and immunomodulating agents
ΔQALY mean
1.730
ICER (Rp/QALY)
2.1 M
✗ above threshold · 0% prob CE @ 1× PDB
L01ED01ΔQALY
crizotinib
Antineoplastic and immunomodulating agents
ΔQALY mean
1.730
ICER (Rp/QALY)
2.1 M
✗ above threshold · 0% prob CE @ 1× PDB
L01EF02ΔQALY
ribociclib
Antineoplastic and immunomodulating agents
ΔQALY mean
1.081
ICER (Rp/QALY)
2.7 M
✗ above threshold · 0% prob CE @ 1× PDB
L01EF03ΔQALY
abemaciclib
Antineoplastic and immunomodulating agents
ΔQALY mean
1.081
ICER (Rp/QALY)
2.7 M
✗ above threshold · 0% prob CE @ 1× PDB
L01FD02ΔQALY
pertuzumab
Antineoplastic and immunomodulating agents
ΔQALY mean
1.928
ICER (Rp/QALY)
283.1 jt
✗ above threshold · 1% prob CE @ 1× PDB
L01FF07ΔQALY
dostarlimab
Antineoplastic and immunomodulating agents
ΔQALY mean
1.107
ICER (Rp/QALY)
5.6 M
✗ above threshold · 0% prob CE @ 1× PDB
L01FF09ΔQALY
tislelizumab
Antineoplastic and immunomodulating agents
ΔQALY mean
1.107
ICER (Rp/QALY)
5.6 M
✗ above threshold · 0% prob CE @ 1× PDB
L01XL03ΔQALY
axicabtagene ciloleucel
Antineoplastic and immunomodulating agents
ΔQALY mean
0.964
ICER (Rp/QALY)
2.1 M
✗ above threshold · 0% prob CE @ 1× PDB
L01XL04ΔQALY
tisagenlecleucel
Antineoplastic and immunomodulating agents
ΔQALY mean
0.964
ICER (Rp/QALY)
2.1 M
✗ above threshold · 0% prob CE @ 1× PDB
L01XL08ΔQALY
lisocabtagene maraleucel
Antineoplastic and immunomodulating agents
ΔQALY mean
0.964
ICER (Rp/QALY)
2.1 M
✗ above threshold · 0% prob CE @ 1× PDB
L02BX03ΔQALY
abiraterone
Antineoplastic and immunomodulating agents
ΔQALY mean
0.710
ICER (Rp/QALY)
6.5 M
✗ above threshold · 0% prob CE @ 1× PDB
L04AB05ΔQALY
certolizumab pegol
Antineoplastic and immunomodulating agents
ΔQALY mean
0.747
ICER (Rp/QALY)
2.4 M
✗ above threshold · 0% prob CE @ 1× PDB
L04AB06ΔQALY
golimumab
Antineoplastic and immunomodulating agents
ΔQALY mean
0.747
ICER (Rp/QALY)
2.4 M
✗ above threshold · 0% prob CE @ 1× PDB
A10BJ02ΔQALY
liraglutide
Alimentary tract and metabolism
ΔQALY mean
0.355
ICER (Rp/QALY)
107.5 jt
✓ acceptable 3× PDB · 25% prob CE @ 1× PDB
A10BJ06ΔQALY
semaglutide
Alimentary tract and metabolism
ΔQALY mean
0.644
ICER (Rp/QALY)
98.8 jt
✓ acceptable 3× PDB · 24% prob CE @ 1× PDB
A10BX16ΔQALY
tirzepatide
Alimentary tract and metabolism
ΔQALY mean
0.300
ICER (Rp/QALY)
72.4 jt
✓ cost-effective · 52% prob CE @ 1× PDB
B01AF03ΔQALY
edoxaban
Blood and blood forming organs
ΔQALY mean
0.331
ICER (Rp/QALY)
22.4 jt
✓ cost-effective · 100% prob CE @ 1× PDB
L01BB04ΔQALY
cladribine
Antineoplastic and immunomodulating agents
ΔQALY mean
0.915
ICER (Rp/QALY)
3.8 M
✗ above threshold · 0% prob CE @ 1× PDB
L01BC07ΔQALY
azacitidine
Antineoplastic and immunomodulating agents
ΔQALY mean
0.915
ICER (Rp/QALY)
3.8 M
✗ above threshold · 0% prob CE @ 1× PDB
L01EC03ΔQALY
encorafenib
Antineoplastic and immunomodulating agents
ΔQALY mean
0.915
ICER (Rp/QALY)
3.8 M
✗ above threshold · 0% prob CE @ 1× PDB
L01EF01ΔQALY
palbociclib
Antineoplastic and immunomodulating agents
ΔQALY mean
0.915
ICER (Rp/QALY)
3.8 M
✗ above threshold · 0% prob CE @ 1× PDB
L01FX04ΔQALY
ipilimumab
Antineoplastic and immunomodulating agents
ΔQALY mean
0.915
ICER (Rp/QALY)
3.8 M
✗ above threshold · 0% prob CE @ 1× PDB
L04AG08ΔQALY
ocrelizumab
Antineoplastic and immunomodulating agents
ΔQALY mean
0.747
ICER (Rp/QALY)
2.4 M
✗ above threshold · 0% prob CE @ 1× PDB
N07BB04ΔQALY
naltrexone
Nervous system
ΔQALY mean
0.052
ICER (Rp/QALY)
-19783 rb
DOMINANT · 98% prob CE @ 1× PDB
R07AX02ΔQALY
ivacaftor
Respiratory system
ΔQALY mean
1.388
ICER (Rp/QALY)
15.8 M
✗ above threshold · 0% prob CE @ 1× PDB
J05AP51ΔQALY
sofosbuvir and ledipasvir
Antiinfectives for systemic use
ΔQALY mean
1.535
ICER (Rp/QALY)
-1915 rb
DOMINANT · 100% prob CE @ 1× PDB
J05AP57ΔQALY
glecaprevir and pibrentasvir
Antiinfectives for systemic use
ΔQALY mean
0.056
ICER (Rp/QALY)
90.4 jt
✓ acceptable 3× PDB · 49% prob CE @ 1× PDB
L01EC01ΔQALY
vemurafenib
Antineoplastic and immunomodulating agents
ΔQALY mean
0.915
ICER (Rp/QALY)
3.6 M
✗ above threshold · 0% prob CE @ 1× PDB
L01EE01ΔQALY
trametinib
Antineoplastic and immunomodulating agents
ΔQALY mean
0.915
ICER (Rp/QALY)
3.6 M
✗ above threshold · 0% prob CE @ 1× PDB
L01EE02ΔQALY
cobimetinib
Antineoplastic and immunomodulating agents
ΔQALY mean
0.915
ICER (Rp/QALY)
3.6 M
✗ above threshold · 0% prob CE @ 1× PDB
L01EK01ΔQALY
axitinib
Antineoplastic and immunomodulating agents
ΔQALY mean
0.915
ICER (Rp/QALY)
3.6 M
✗ above threshold · 0% prob CE @ 1× PDB
L01FE02ΔQALY
panitumumab
Antineoplastic and immunomodulating agents
ΔQALY mean
0.915
ICER (Rp/QALY)
3.6 M
✗ above threshold · 0% prob CE @ 1× PDB
L01FF13ΔQALY
toripalimab
Antineoplastic and immunomodulating agents
ΔQALY mean
0.887
ICER (Rp/QALY)
7.9 M
✗ above threshold · 0% prob CE @ 1× PDB
L01XX27ΔQALY
arsenic trioxide
Antineoplastic and immunomodulating agents
ΔQALY mean
0.915
ICER (Rp/QALY)
3.6 M
✗ above threshold · 0% prob CE @ 1× PDB
L04AC03ΔQALY
anakinra
Antineoplastic and immunomodulating agents
ΔQALY mean
0.747
ICER (Rp/QALY)
2.4 M
✗ above threshold · 0% prob CE @ 1× PDB
L04AE01ΔQALY
fingolimod
Antineoplastic and immunomodulating agents
ΔQALY mean
0.253
ICER (Rp/QALY)
43.4 jt
✓ cost-effective · 73% prob CE @ 1× PDB
M09AX10ΔQALY
risdiplam
Musculo-skeletal system
ΔQALY mean
0.253
ICER (Rp/QALY)
43.4 jt
✓ cost-effective · 73% prob CE @ 1× PDB
N02CD01ΔQALY
erenumab
Nervous system
ΔQALY mean
0.255
ICER (Rp/QALY)
3.2 M
✗ above threshold · 0% prob CE @ 1× PDB
N02CD02ΔQALY
galcanezumab
Nervous system
ΔQALY mean
0.255
ICER (Rp/QALY)
3.2 M
✗ above threshold · 0% prob CE @ 1× PDB
N02CD03ΔQALY
fremanezumab
Nervous system
ΔQALY mean
0.255
ICER (Rp/QALY)
3.2 M
✗ above threshold · 0% prob CE @ 1× PDB
N02CD05ΔQALY
eptinezumab
Nervous system
ΔQALY mean
0.255
ICER (Rp/QALY)
3.2 M
✗ above threshold · 0% prob CE @ 1× PDB
N07BA03ΔQALY
varenicline
Nervous system
ΔQALY mean
0.146
ICER (Rp/QALY)
1.7 jt
✓ cost-effective · 100% prob CE @ 1× PDB
B03XA01ΔQALY
erythropoietin
Blood and blood forming organs
ΔQALY mean
0.166
ICER (Rp/QALY)
772.1 jt
✗ above threshold · 0% prob CE @ 1× PDB
B03XA02ΔQALY
erythropoiesis-stimulating agents
Blood and blood forming organs
ΔQALY mean
0.166
ICER (Rp/QALY)
772.1 jt
✗ above threshold · 0% prob CE @ 1× PDB
B03XA03ΔQALY
methoxy polyethylene glycol-epoetin beta
Blood and blood forming organs
ΔQALY mean
0.166
ICER (Rp/QALY)
4.1 M
✗ above threshold · 0% prob CE @ 1× PDB
Engine: parametric Markov state-transition + PSA Monte Carlo + tornado one-way sensitivity. Card membuka laporan dari awal agar pembaca melihat konteks sebelum masuk ke hasil ekonomi.
Eksperimen · Draft v0.1

HTA Report Generator — AI-baseline per drug.

Otomasi dokumen HTA untuk Indonesia. Setiap obat di master list bisa di-generate menjadi dokumen 10-section terstruktur — dipopulasi otomatis dari NICE + WHO EML + Fornas + INAPROC. Baseline ini adalah starting point untuk full review oleh medical writer, health economist, dan InaHTAC.

65
Drug Prioritas 1
siap di-generate
Lihat seluruh 65 drug Prioritas 1, masing-masing bisa di-generate report HTA-nya.Daftar lengkap Prioritas 1 →